Blood Oligodendrocyte Exosome Testing for Asymptomatic Brain Injury
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for subconcussive brain injuries lack sensitivity and specificity, failing to detect subtle brain damage in asymptomatic individuals due to the brain's ability to compensate for injuries through alternative neural pathways, and existing blood-based biomarkers peak shortly after injury, making them unsuitable for monitoring recovery processes.
Innovation Solution
A blood test format utilizing oligodendrocyte-derived exosomes (ODEs) to detect biomolecules like BDNF, NRG1, and CNTF, which are released into the bloodstream and can monitor post-trauma cellular cascades, offering a non-invasive means to identify and assess the severity of asymptomatic brain trauma using as little as 5 μL of plasma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current blood-based biomarkers (neuronal and glial proteins) are used for diagnosis, then severe TBI can be detected, but minor cellular and molecular damage cannot be detected
Solution Approach 1:
The patent uses exosomes as intermediary carriers that transport biomolecules from injured brain cells to the bloodstream. By detecting these exosome-bound biomarkers, the system achieves high sensitivity for minor injuries while maintaining diagnostic reliability, resolving the contradiction between detection sensitivity and diagnostic accuracy
Solution Approach 2:
The patent shifts the detection parameter from intracellular proteins (GFAP, UCHL1) to exosome-bound biomolecules (BDNF, NRG1, CNTF). This parameter change enables detection of subtle cellular stress responses before cell death occurs, improving both sensitivity for minor injuries and reliability of diagnosis across the injury spectrum
2Measurement precision
If existing blood biomarkers are measured, then injury detection is possible, but they peak shortly after injury and cannot monitor recovery processes
Solution Approach 1:
The patent employs dynamic monitoring of exosome biomarker levels over time. Since exosomes are continuously released during both acute injury and recovery phases, and their biomarker profiles change dynamically throughout the healing process, this enables extended detection windows that capture both initial injury and subsequent recovery trajectories
Solution Approach 2:
The patent leverages the continuous release of exosomes throughout the injury and recovery timeline. Unlike intracellular proteins that peak and decline rapidly, exosome-bound biomarkers provide continuous information about cellular status, enabling uninterrupted monitoring from acute injury through chronic recovery phases
3Ease of operation
If physical examinations and standardized assessments are used, then concussion management decisions can be made, but objective and quantitative methods are limited
Solution Approach 1:
The patent replaces subjective physical examinations and standardized cognitive tests with an objective biochemical assay system. The immunoassay-based detection of exosome biomarkers provides quantitative, objective measurements that eliminate rater subjectivity while maintaining clinical feasibility through simple blood draw procedures
Solution Approach 2:
The patent transitions from behavioral and physical performance parameters (reaction time, balance scores) to molecular biomarker parameters (BDNF, NRG1, CNTF concentrations). This parameter change provides objective quantification of brain injury and recovery while preserving ease of clinical operation through blood-based testing
Data Source
AI summary
Methods of identifying and assays designed to identify at least one biomolecule from a patient are disclosed that comprise: collecting at least one biofluid from a patient, isolating at least one exosome from the biofluid, and identifying at least one biomolecule from the at least one exosome, wherein the at least one biomolecule is bound to the at least one exosome and is locally released from the patient. In some embodiments, the at least one biomolecule comprises a secretory protein, a neurotrophic factor, a growth factor, a cytokine, a chemokine, a pre-toxic molecule, a toxic molecule, or a combination thereof.